We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care.

The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn business and further develop our growing wound care portfolio. Granudacyn effectively cleanses wounds, which supports healing, ultimately helping to ease the burden of wounds

Mölnlycke’s purpose is to revolutionise care for people and planet. In the Antiseptics business area, we do this by making patient skin decolonisation manageable and motivational. We believe that Steriwave can improve the lives of millions of people, fitting perfectly with our purpose and mission. The ability to rapidly eliminate multiple drug-resistant pathogens without generating antimicrobial resistance is key to our sustainability initiative, and complements our Hibiwash® brand skin prep line, enabling us to provide comprehensive ‘nose-to-toes’ decolonisation prior to surgery. Universal decolonisation is now a well-accepted practice to improve surgical outcomes and produce significant cost savings to healthcare systems.

We are excited to be partnering with Mölnlycke Health Care, whose global reach, corporate vision and commitment to sustainable healthcare aligns perfectly with our own core values, purpose and mission. The Mölnlycke collaboration represents a transformative step towards our ambitious plans to combat HAIs and antimicrobial resistance globally. We look forward to working with Mölnlycke in these initial key markets and beyond.

We are very excited to make this strategic investment in MediWound. It aligns with our strategy to bring radical innovations into the wound care space and provide alternative solutions to the more traditional debridement options to improve clinical outcomes and patient experience. This investment will support Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and I look forward to this partnership.

We are delighted to have Mölnlycke’s support. This substantial investment will empower us to strengthen our strategic plans, creating significant long-term value for our stakeholders and help to improve standards of care for patients

“To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.”

“This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.”

“I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.”

The state of Kedah is very proud to be the host of Mölnlycke’s new state-of-the-art factory, and in being recognised as a state providing the right prerequisites for sustainable production of high-quality surgical gloves, and in enabling Mölnlycke to live its vision to improve hand performance for health care professionals across the globe – because hands deserve better.

Mölnlycke’s decision to continue and expand its operations here in Kulim is a clear indicator of the successful story of Malaysian manufacturing in particular here in Kedah. In return, Mölnlycke, a global leader within MedTech, will be able to increase its competitiveness on the global market. This is a story of successful cooperation, a win-win, between Mölnlycke – Kulim and Kedah, which is also the story of our two countries. Sweden and Malaysia have a great history of producing win-wins and we will continue to do so.

here is a lot to be proud of when working at Mölnlycke. When future generations look back at our history, I am convinced they will see this day as a milestone – as we take yet another step on our journey to become a global leader in sustainable healthcare production and supply and a leading employer in the global healthcare sector.

The new plant is a key part of our future plans for sustainable growth within the surgical gloves business. It will enable us to expand production to meet projected demand. But the best part is that we will achieve this in a less resource intensive way, at the same time offering a state-of-the-art working environment for our colleagues in Malaysia

The surgical gloves manufacturing process is resource intensive. By partnering with experts in the fields of energy management and water management, we ensure we act to realise our ambition to become a global leader in sustainable healthcare. I am very pleased with the partnerships with ENGIE and Veolia – they are important in bringing to life ‘WeCare’, Mölnlycke’s sustainability transformation agenda for the Gloves business area.

ENGIE is proud to be the chosen long-term sustainability partner to Mölnlycke in accelerating their low-carbon journey in Malaysia. This will be an important milestone for our partnership, helping the Kulim plant use as little energy as possible. More broadly, the project exemplifies how industry players can reap economic benefits by accelerating their energy transition with low-carbon solutions.

Veolia is firmly committed to championing ecological transformation. We are excited to partner with companies like Mölnlycke, who seek to establish sustainable practices and integrate a green mindset into their business. Our team is proud to be part of Mölnlycke's expansion plans in Malaysia and we look forward to more avenues to support their endeavour for greater sustainability and improved performance.

Our aim is to ensure the healthcare professionals we work with in the UK have the tools needed to continue patient care, even in the uncertain times ahead. We see the UK distribution centre as essential to how we operate here in the UK as a way of minimising the impact that wider national and global situations may have on our product supply.

In addition to the immediate benefits with regards to efficient supply chain and reduced carbon footprint, the new UK distribution centre provides new and exciting opportunities for us to explore additional logistical services to benefit customers in the future.

Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region

This exciting new technology will help reduce the incidence of serious infection and minimise the unnecessary use of antibiotics.

This is fully in line with where we want to be as a company, and M&J’s strong R&D capabilities combined with Mölnlycke’s end-product knowledge will help us further improve our competitive position within the advanced wound care industry.

We believe that the Mepilex Border Flex dressing may change the way wound care experts practice

'Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. '

Mӧlnlycke’s dedication to pressure injury prevention is an example of our shared commitment with the WOCN Society

These market practices that allow extrapolation of evidence from one specific product to another similar type of product, even though the latter is not equivalent in material construction and design to the former, can put patients at risk.

Compared with the rigorous and thorough processes in place within the pharmaceutical industry for extrapolation of clinical evidence of efficacy from one product to another, parts of the medical devices industry is operating in a grey zone.

Healthcare systems are under pressure to deliver better care to more people with a better value. Right now, healthcare is focused on outcomes. By focusing on prevention issues, you are able to help reduce some costs to the healthcare systems. Our solutions are designed to help reduce the risk of infection, hospital readmissions, and hospital acquired conditions. These are things that can lead to much higher costs, much higher patient suffering, and longer length of stay.

Hibiclens isn’t just for the hospital – it also works in the home. That is why we continue to expand our retail availability to make it easier for consumers to buy Hibiclens. Because it bonds to your skin and has 24-hour protection, you’re able to resist the multitude of germs you come across in your daily lives.

Mölnlycke is doing things right. Healthcare should always come first.

Our solutions are true to Mölnlycke’s purpose of advance performance in healthcare across the world. When looking at the patient and caregiver experience, we aspire to equip both with solutions to achieve the best outcomes. This is why we care about prevention of Surgical Site Infections. Simply put, we know they are a significant issue impacting patient care and increasing health care costs and we want to be the best partner in making a positive difference in this space.

Continued caregiver and patient understanding is important to us and central to what we call having ‘Customer at Heart’. Combined with our gained expertise and advanced technologies, we’ve developed a portfolio of SSI bundle solutions for perioperative care. Mölnlycke truly believes that together we can make a difference. Everyone involved - the patient, health care provider, the care facility and our healthcare system overall- benefits when we are able to work together to reduce infection rates.

Tissue Analytics is incredibly excited to work with Mölnlycke on this important initiative. We share the same passion to help patients.

We are very excited to be part of AstraZeneca’s BioVentureHub, as it offers a unique opportunity for us to collaborate with AstraZeneca’s world-class scientists and benefit from their state-of-the-art facilities and infrastructure while developing new advanced wound care and surgical solutions for our customers.

It’s fantastic that a well-established, global, medical solutions company like Mölnlycke wants to be part of our innovation experiment.

Our strong focus on product innovation and clinical evidence has continuously changed the way wounds are treated and prevented.

This reconfirms market confidence in Mölnlycke and our sound, long-term corporate strategy

Skin protectants are strategically important to our Prevention solution offer and the partnership with Rochal enables us to provide our customers with a complete solution within the pressure ulcer prevention area

It is our hope that the WUWHS consensus document will help clinicians and health care budget holders understand the role of dressings in PU prevention, as well as which dressings may protect against PU development and which patients may benefit.

The results of this research will contribute to developing a better understanding of the hidden costs of wound care and also, ultimately, to better patient care.

We finally have a product that really works; this is fantastic news for cancer patients.

The BARRIER EasyWarm active self-warming blanket is a welcome addition to the tools available to healthcare professionals

being granted FDA clearance gives us access to another important market, where we will launch during 2014